MUNASET | Multiparametric nanoelectronic biosensors for therapy response testing

Summary
Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer, and immune system disorders. However, there is a lack of tools for real-time activity analysis of disease-related protease biomarkers. To address this issue, we propose to develop a highly sensitive graphene-based biosensor platform for parallel detection of multiple proteases in serum. We will exploit a new label-free sensing mechanism based on charge removal due to cleavage of designer peptides by proteases. As a specific business case, we plan to address therapy response prediction along treatment of major depressive disorder (MDD). MDD is one of the most common and burdensome mental disorders worldwide. MDD is also among the most expensive brain diseases in Europe. While effective treatments exist, there is a high variability in treatment response. There are no serum-based tests to predict personalized therapy for MDD patients. The effective treatment is identified through trial and error, a great burden for patients and the health care system. A rapid, sensitive and easy-to-use test would allow faster and more precise treatment identification, improving therapy outcomes and reducing hospitalization times. Here, we plan to detect two protease biomarkers associated with MDD. The biosensors will be validated in clinical serum samples. Arrays of graphene biosensors will be integrated on silicon wafers with a multiplexed readout matrix to realize a miniaturized sensor system with multi-analyte detection capability, high dynamic range, high precision, low detection limit, and low material consumption. The resulting platform technology may enable various point-of-care diagnostic and therapy prediction tools. This will help secure industrial leadership of the EU over the entire value chain of novel graphene-based bio-analytical tools.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/101119473
Start date: 01-10-2023
End date: 30-09-2027
Total budget - Public funding: 4 000 206,25 Euro - 4 000 206,00 Euro
Cordis data

Original description

Proteases recently emerged as a promising new class of biomarkers with a broad diagnostic, prognostic and therapeutic potential for different human diseases including neurological and psychiatric diseases, several types of cancer, and immune system disorders. However, there is a lack of tools for real-time activity analysis of disease-related protease biomarkers. To address this issue, we propose to develop a highly sensitive graphene-based biosensor platform for parallel detection of multiple proteases in serum. We will exploit a new label-free sensing mechanism based on charge removal due to cleavage of designer peptides by proteases. As a specific business case, we plan to address therapy response prediction along treatment of major depressive disorder (MDD). MDD is one of the most common and burdensome mental disorders worldwide. MDD is also among the most expensive brain diseases in Europe. While effective treatments exist, there is a high variability in treatment response. There are no serum-based tests to predict personalized therapy for MDD patients. The effective treatment is identified through trial and error, a great burden for patients and the health care system. A rapid, sensitive and easy-to-use test would allow faster and more precise treatment identification, improving therapy outcomes and reducing hospitalization times. Here, we plan to detect two protease biomarkers associated with MDD. The biosensors will be validated in clinical serum samples. Arrays of graphene biosensors will be integrated on silicon wafers with a multiplexed readout matrix to realize a miniaturized sensor system with multi-analyte detection capability, high dynamic range, high precision, low detection limit, and low material consumption. The resulting platform technology may enable various point-of-care diagnostic and therapy prediction tools. This will help secure industrial leadership of the EU over the entire value chain of novel graphene-based bio-analytical tools.

Status

SIGNED

Call topic

HORIZON-CL4-2022-DIGITAL-EMERGING-02-19

Update Date

12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon Europe
HORIZON.2 Global Challenges and European Industrial Competitiveness
HORIZON.2.4 Digital, Industry and Space
HORIZON.2.4.0 Cross-cutting call topics
HORIZON-CL4-2022-DIGITAL-EMERGING-02
HORIZON-CL4-2022-DIGITAL-EMERGING-02-19 2D materials-based devices and systems for biomedical applications (RIA)
HORIZON.2.4.3 Emerging enabling technologies
HORIZON-CL4-2022-DIGITAL-EMERGING-02
HORIZON-CL4-2022-DIGITAL-EMERGING-02-19 2D materials-based devices and systems for biomedical applications (RIA)